北京天坛生物制品股份有限公司关于下属企业获得药物临床试验批准通知书的公告

Core Viewpoint - Beijing Tiantan Biological Products Co., Ltd. announced that its subsidiary, Kunming Blood Products Co., Ltd., has received the Clinical Trial Approval Notice from the National Medical Products Administration for the clinical trial of "Human Fibrinogen" [1] Group 1: Product Information - The product "Human Fibrinogen" is set to undergo clinical trials following the approval [1] Group 2: Market Situation - The domestic market information is sourced from the National Medical Products Administration's official website [1] - International market details were not disclosed in the announcement [1] Group 3: Approval Process - The product must complete several steps including clinical trials, submission of drug marketing authorization application, review by the National Medical Products Administration, and obtaining a drug registration certificate before it can be produced and marketed [1]